Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen To Extend Enbrel Cancer, Autoimmune Safety Study By Five Years

This article was originally published in The Pink Sheet Daily

Executive Summary

The company satisfied a prior post-marketing commitment to collect five-year data on cancer and autoimmune disease development but will now extend that follow-up period to a total of 10 years, an FDA approval letter for labeling revisions to the TNF inhibitor says.

You may also be interested in...

J&J's Remicade Adds Malignancy Warning To Labeling

New language on lymphoma in the Warnings and Adverse Reactions sections of labeling is substantially similar to that of other TNF-inhibitors – Amgen's Enbrel and Abbott's Humira. J&J is issuing a "Dear Doctor" letter to inform physicians of the changes.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT

QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts